skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Emerging treatments for premature ejaculation: focus on dapoxetine

Review

(6214) Views  (1283) Full article downloads

Authors: Wayne JG Hellstrom

Published Date December 2008 Volume 2009:5 Pages 37 - 46
DOI: http://dx.doi.org/10.2147/NDT.S3251

Wayne JG Hellstrom

Chief, Section of Andrology, Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA

Abstract: Premature ejaculation (PE) is a common problem in men worldwide. It has a significant impact on affected men and their partners in terms of self-esteem, dissatisfaction with their sexual relationships, personal distress, and interpersonal difficulty. Psychological therapies may achieve short-term improvements, but there are limited data on the long-term success of these methods. Oral therapy with long-acting selective serotonin reuptake inhibitors (SSRIs) improves intravaginal ejaculatory latency time (IELT), but these agents are designed to be administered daily and may be associated with unwanted sexual side effects and withdrawal symptoms upon abrupt discontinuation. Dapoxetine is a short-acting SSRI that can be taken as needed (prn) by men with PE. It has been studied in five separate multicenter, randomized, double-blind, placebo-controlled trials involving more than 6000 men with PE. In four studies that evaluated IELT as an endpoint (N = 4843), dapoxetine 30 and 60 mg prn achieved statistically significant increases in IELT versus placebo. Dapoxetine also showed statistically significant improvements in perceived control over ejaculation, PE-related personal distress, and other patient-reported outcomes in all five trials. Dapoxetine treatment is generally well-tolerated, with low incidences of discontinuation syndrome, sexual dysfunction, and treatment-emergent mood symptoms. The most common adverse events with dapoxetine included nausea, diarrhea, headache, dizziness, and somnolence.

Keywords: dapoxetine, discontinuation syndrome, premature ejaculation, selective serotonin reuptake inhibitor








Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Potential renovascular hypertension, space missions, and the role of magnesium
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation
Everolimus-eluting stents: update on current clinical studies